Neolytica - A QPharma Company
Shubi Randhawa, Ph.D., is a Senior Manager of Consulting at Neolytica - A QPharma Company since April 2023. Prior to this role, Shubi held various positions at Neovation Consultancy Services from June 2021 to April 2023, including Head of Digital and Senior Manager of Medical Projects. Shubi's academic background includes a Doctor of Philosophy in Experimental Therapeutics from UT MD Anderson Cancer Center UTHealth Houston, supplemented by a Master's degree in Cancer Cell & Molecular Biology from the University of Leicester and a Bachelor's degree in Biotechnology from the University of Hertfordshire. Previous professional experiences include serving as a Senior Demonstrator at the Sanjay Gandhi Postgraduate Institute of Medical Sciences and a Graduate Research Assistant at MD Anderson Cancer Center, where significant research on cell adhesion in leukemia was conducted. Additionally, Shubi has served as a Freelance Scientific Editor and volunteered for patient support services at MD Anderson.
This person is not in any teams
This person is not in any offices
Neolytica - A QPharma Company
A subsidiary of QPharma, Neolytica brings solutions and a portfolio of products that leverage cutting edge technologies like AI and Data Analytics to deliver significant value in strategic and operational aspects of Medical Affairs, Market Access, Commercial Marketing and Commercial Sales. Our offerings portfolio includes: Ti Expert : This technology and consulting solution brings comprehensive access to data about highly qualified and validated medical professionals, including professional spheres of influence, social relationships, and promotional activities. NotifyMe : A Healthcare KOL engagement service with email alerts. An application that enables enterprise-scale social listening and provides actionable alerts on healthcare stakeholders in a desired therapeutic area. Ti Risk : Dependence on Opioid has increased burden on patients, employers, insurers, society, and the health care system. Our product aims to address this by identifying prescribers and patients that are potentially involved in diversion of opioids by following patient journey and prescriber behaviour, along with supplementary secondary research – Real-time and At-risk scoring analysis. For more details, visit - www.neolytica.ai